Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Breakthrough CardiAMP Cell Therapy System Discovered for Heart Failure

BioCardia®, Inc discovered breakthrough CardiAMP® Cell Therapy System for the treatment of heart failure.

CardiAMP Cell Therapy makes use of patients own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. It uses pre-procedural screening assay which can detect patients who are first to receive cardiac cell therapy enhancing patient selection.

CardiAMP Cell Therapy is designed to potentially improve the body’s natural healing response causing a beneficial paracrine reaction to repair the heart.

Compared to other therapies the action of mechanism is different which transforms stem cells into new heart cells resulting in patient risks, such as rhythm abnormalities and cell rejection. In addition, this cell therapy significantly improves the patients life struggling with heart failure.

This therapy provides new treatment options for patients in need and fastens the procedure compared to other traditional methods.

The CardiAMP Cell Therapy Heart Failure Trial is currently under trial to evaluate the significance of CardiAMP Cell Therapy System in lowering adverse cardiac events, increasing survival rates and improving quality of life for patients. It has the potential in providing more effective treatment for heart failure.

U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024